A Safety and Efficacy Study Comparing the Combination Treatments of Verteporfin Therapy Plus One of Two Different Doses of Intravitreal Triamcinolone Acetonide and the Verteporfin Therapy Plus Intravitreal Pegaptanib

Inclusion Criteria: * age \>50 * all types of untreated subfoveal choroidal neovascularization secondary to AMD * lesion size \<5400 microns in greater linear dimension (GLD) Exclusion Criteria: * have a history of prior photodynamic therapy, external beam radiation, subfoveal focal laser photocoagulation, submacular surgery, or transpupillary thermotherapy * known allergy to verteporfin, triamcinolone or pegaptanib * have received prior treatment with Macugen, or other anti-angiogenic compound or any investigational treatment (e.g. Ruboxistaurin, Lucentis \[ranibizumab\], Retaane \[anecortave acetate\], squalamine, siRNA, VEGF-Trap etc.) for neovascular AMD * have the presence of fibrosis, hemorrhage, pigment epithelial detachments, tear (tip) of the retinal pigment epithelium or other hypoflourescent lesions obscuring greater than 50% of the CNV lesion * have had previous pars plana vitrectomy in the study eye Other protocol-specified inclusion/exclusion criteria applied.